New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Plasma cells (PCs) are the terminal differentiation stage of activated B cells and serve as crucial effector cells in humoral immunity. While PCs have ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

The following is a summary of “Fasting plasma methylglyoxal concentrations are associated with higher numbers of circulating intermediate and non-classical monocytes but with lower activation of ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

The small San Diego biotech developed the drug candidate after screening “convalescent” plasma ... cells. STI-1499 was a most potent, completely neutralising virus infectivity at a very low ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

In this event, the plasma, which is usually group O transfused to A, B or AB recipients, may contain sufficient potent antibodies directed against A or B antigens on the recipient's red cells to ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...